Caribou Biosciences (CRBU) announced the FDA granted Fast Track designations to CB-010 for refractory systemic lupus erythematosus and to CB-012 for relapsed or refractory acute myeloid leukemia. CB-010 will be evaluated in the GALLOP Phase 1 clinical trial in patients with lupus nephritis and extrarenal lupus, subcategories of SLE. The GALLOP clinical trial is on track to initiate by year-end 2024.
CB-012 is being evaluated in the ongoing AMpLify Phase 1 clinical trial in patients with r/r AML.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.